Recurrent Solid Neoplasm Recruiting Phase 1 Trials for DB08911 (Trametinib)

IndicationStatusPhase
DBCOND0080814 (Recurrent Solid Neoplasm)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02097225Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTreatment